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A B S T R A C T
Objectives: Head and neck squamous cell carcinoma (HNSCC) is often associated with chronic systemic in-
ﬂammation (SI). In the present study, we assessed if DNA methylation-derived SI (mdSI) indices: Neutrophil-to-
Lymphocyte ratio (mdNLR) and Lymphocyte-to-Monocyte ratio (mdLMR) are associated with the presence of
HNSCC and overall survival (OS).
Materials and methods: We used two peripheral blood DNA methylation datasets: an HNSCC case-control dataset
(n=183) and an HNSCC survival dataset (n=407) to estimate mdSI indices. We then performed multivariate
regressions to test the association between mdSI indices, HNSCC development and OS.
Results: Multivariate logistic regression revealed that elevated mdNLR was associated with increased odds of
being an HNSCC case (OR=3.25, 95% CI= 2.14–5.34, P=4×10−7) while the converse was observed for
mdLMR (OR=0.88, 95% CI=0.81–0.90, P= 2×10−3).
In the HNSCC survival dataset, HPV16-E6 seropositive HNSCC cases had an elevated mdLMR (P=9×10−5)
and a lower mdNLR (P=0.003) compared to seronegative patients. Multivariate Cox regression in the HNSCC
survival dataset revealed that lower mdLMR (HR=1.96, 95% CI=1.30–2.95, P=0.0013) but not lower
mdNLR (HR=0.68, 95% CI=0.46–1.00, P= 0.0501) was associated with increased risk of death.
Conclusion: Our results indicate that mdSI estimated by DNA methylation data is associated with the presence of
HNSCC and overall survival. The mdSI indices may be used as a valuable research tool to reliably estimate SI in
the absence of cell-based estimates. Rigorous validation of our ﬁndings in large prospective studies is warranted
in the future.
Introduction
Head and neck squamous cell carcinoma (HNSCC) includes cancers
arising from the lining epithelium of the upper aero-digestive tract in-
cluding the oral cavity, larynx, pharynx, and nasopharynx [1]. Globally,
HNSCC accounts for nearly 600,000 newly diagnosed cancer cases
leading to approximately 325,000 deaths each year [2]. Tobacco and
alcohol abuse are the main risk factors for HNSCC [1]. However, high-
risk types of human papillomavirus (HPV), especially HPV type 16 have
emerged as risk factors in a subset of HNSCC, particularly orophar-
yngeal cancer (OPC) [3]. Disease stage has been the single most pre-
dictive prognostic factor for OPC [4], although recent studies point to
HPV status as an independent marker of prognosis in HNSCC patients
[5,6].
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Cancer related chronic systemic inﬂammation (SI) is an enabling
characteristic of cancers which help them to acquire tumour hallmarks
[7] and its role in cancer prognosis has been increasingly recognised
[8]. Chronic SI also promotes tumour initiation and progression by
induction of immunosuppression via Myeloid Derived Suppressor Cells
(MDSCs) [9]. Indeed, HNSCC is often associated with im-
munosuppression, with an imbalance in both the composition and
function of eﬀector immune cells [10].
The SI response can be clinically measured by assessing circulating
leukocyte ratios and/or acute phase proteins like C-reactive protein
(CRP) [11,12]. In particular, the leukocyte subtype ratios like Neu-
trophil-to-Lymphocyte ratio (NLR) and Lymphocyte-to-Monocyte ratio
(LMR) have shown promise as prognostic markers in many solid tu-
mours [13] including HNSCC [14–22]. However, leukocyte measures
are not readily available in many studies, especially in prospective
cohorts [19].
DNA methylation based cell-type deconvolution algorithms have
shown promise in estimating leukocyte cell type proportions [23]. Two
recent studies have shown the utility of generating a methylation-de-
rived NLR (mdNLR) index from peripheral blood DNA as a marker of
cancer development and progression [19,24]. Furthermore, the authors
reported a strong agreement between mdNLR and cell count based NLR
estimates, instilling conﬁdence in the DNA methylation based estimates
of leukocytes and methylation-derived SI.
In the present study, we estimated mdSI indices (mdNLR and
mdLMR) in pre-treatment HNSCC cases, cancer free controls, and in an
independent set of HNSCC patients with overall survival (OS) data. We
evaluated whether mdSI indices are associated with the presence of
HNSCC and OS.
Material and methods
HNSCC case-control dataset
The DNA methylation data, percentage of leukocyte subtypes and
covariates for the HNSCC case-control dataset were kindly provided by
co-authors (DCK and KTK, GEO accession: GSE30229).
The study consisted of 92 pre-treatment HNSCC cases and 92
cancer-free control subjects with DNA methylation data from peripheral
blood samples. The cases and controls were frequency-matched on age
and gender. Details about the sample selection and preparation have
been described previously [25]. DNA methylation was assessed using
the Illumina Inﬁnium HumanMethylation27 BeadChip assay (Illumina,
Inc., CA, USA). To avoid potential biases, HNSCC case and control
samples were randomized to bead chips. A sample with an unusually
high value of mdLMR (mdLMR=1116) was considered an outlier and
was removed leaving a total of 91 HNSCC cases and 92 cancer-free
controls for the ﬁnal analysis.
HNSCC survival dataset
The study population for this analysis was comprised of individuals
enrolled in the Head and Neck 5000 clinical cohort study [26,27].
Brieﬂy, 5511 people with a new head and neck cancer diagnosis were
recruited from 76 centres across the UK between April 2011 and De-
cember 2014. Individuals were recruited before they started treatment
unless their treatment was their diagnostic procedure. Full ethical ap-
proval was granted by The South West – Frenchay Regional Ethics
Committee (ref: 10/H0107/57).
At baseline, participants were asked to complete three self-ad-
ministered questions, which included questions on socio-economic
circumstances, lifestyle, general health and past sexual behaviours.
Biological samples (blood (n=4676 (85%), saliva (n=4986 (90%)
and tissue) were collected from all consenting participants. Information
on stage at diagnosis, treatment and various other clinical and patho-
logic prognostic variables were abstracted from participants’ medical
records. 5474 (99%) data capture forms and 4099 (74%) health and
lifestyle questionnaires were completed [27].
The participants were selected for DNA methylation proﬁling based
on ICD-10 coding of OPC (C01, C05.1, C05.2, C05.8, C09.0, C09.1,
C09.8, C09.9, C10.0, C10.2, C10.3, C10.8, C10.9) and availability of
OncoChip genotype data [28]. They were also selected on the basis of
complete baseline questionnaire and data capture information, as well
as the availability of both blood and saliva samples taken at baseline. To
date, DNA samples isolated from buﬀy coats have been analysed for 448
participants.
Blood samples were frozen and stored at−80 °C and then processed
in the Bristol Bioresource Laboratories. Following extraction, DNA was
bisulphite-converted using the EZ DNA MethylationTM kit (Zymo,
Irvine, CA, USA) as per the previously published protocol [29]. Fol-
lowing conversion, genome-wide methylation status of over 850,000
CpG sites was measured using the Inﬁnium MethylationEPIC BeadChip
[30]. The arrays were scanned using Illumina iScan and the initial
quality review was assessed using GenomeStudio. DNA methylation
data for the HNSCC survival dataset has not been previously published.
During the data generation process, a wide range of batch variables
were recorded in a purpose-built laboratory information management
system (LIMS).
Quality control and normalisation
Raw data (IDAT ﬁles) from GenomeStudio were loaded into R
package meﬃl [31] and quality control (QC) data extracted (Supple-
mentary Fig. 1). In total, 5 samples failed at least one of the QC steps.
Overall, 443 samples passed the QC. Due to the subsequent recoding of
the ICD-10 classiﬁcations, we had 436 samples of the oral cavity and
oropharyngeal cancers. After ﬁltering for the samples with complete
data on HPV status, alcohol consumption and smoking status, we were
left with 407 samples for the ﬁnal analysis. These samples consisted of
389 OPC and 18 oral cancer cases.
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.oraloncology.2018.08.
021.
Following QC, we performed functional normalization which ex-
ploits control probes to separate biological variation from technical
variation [32]. Data were normalised using six control probe principal
components derived from the technical probes.
Tobacco, alcohol, comorbidity and HPV exposure
Detailed information on tobacco and alcohol history was obtained at
baseline via the self-reported questionnaire. Participants were asked
about their use of tobacco and alcohol products prior to receiving their
HNSCC diagnosis.
Smoking status was deﬁned as “ever” (current and former) or
“never”. Former smokers were those that reported having smoked
≥100 cigarette in a lifetime, whilst never smokers were deﬁned as
having never smoked at least one daily cigarette during a whole year.
Respondents were asked to report their average weekly alcohol
consumption and were deﬁned as “ever” and “never”.
Chronic diseases are associated with increased systemic inﬂamma-
tion [33]. We used the Adult Comorbidity Evaluation 27 (ACE 27)
completed by research nurses in clinical centres to record the presence
and severity of medical comorbidities including chronic systemic dis-
eases as described by Piccirillo et al. [34]. The participants were
grouped into four categories: no co-morbidity, mild comorbidity;
moderate decompensation and severe decompensation.
HPV serologic testing (HPV16 E6, E7, E1, E2, E4, and L1) was
conducted at the German Cancer Research Center (DKFZ, Heidelberg,
Germany) using glutathione S-transferase fusion protein-based multi-
plex serology [35]. HPV16 E6 antibodies have been shown to have
potential diagnostic and/or prognostic capabilities in HPV-positive OPC
[36]. We dichotomized the median ﬂuorescence intensity (MFI) values
to indicate HPV16 E6 seropositivity using a cut-oﬀ of≥1000 MFI [37].
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Mortality data
Regular updates are received from the NHS Central Register
(NHSCR) and the NHS Information Centre (NHSIC) notifying on sub-
sequent cancer registrations and mortality among cohort members
throughout the Head and Neck 5000 study. Recruitment for the study
ﬁnished in December 2014 and follow-up information on mortality
status was obtained in September 2017, resulting in at least 2.75 years
of follow-up for all participants.
Estimating cell counts and computing the methylation-derived systemic
inﬂammation indices
For the HNSCC case-control dataset, cell counts were estimated as
previously described [19,38]. For the HNSCC survival dataset, we used
the dataset from Reinius et al. as a cell type reference [39] and cell
counts were estimated using the Houseman et al. algorithm for esti-
mating cell counts [38] in meﬃl. Each sample was normalised in-
dividually to the cell type reference, thus avoiding having cell count
estimates dependent on other samples being included in the normal-
isation.
Methylation derived Neutrophil-to-Lymphocyte Ratio (mdNLR) was
estimated by dividing estimated proportions of granulocytes by lym-
phocytes as previously described [19]. Similarly, methylation derived
Lymphocyte-to-Monocyte Ratio (mdLMR) was estimated by dividing
estimated proportions of lymphocytes by monocytes.
Statistical analyses
The analyses were performed using statistical software R (version
3.4.0). A Wilcoxon rank sum test was used to compare the mean mdNLR
and mdLMR in (a) HNSCC cases and cancer free controls (from the
HNSCC case-control dataset) and (b) HNSCC cases with available OS
data (from the HNSCC survival dataset).
Multivariate logistic regressions were performed to test the asso-
ciation between mdNLR (continuous), mdLMR (continuous) and
HNSCC case-control status. To test the association of mdSI indices
(categorical, above and below median) with OS, univariate and multi-
variate Cox proportional hazard analysis was performed in the HNSCC
survival dataset.
Prior to testing associations in the HNSCC case-control dataset, any
potential eﬀect of plate and/or BeadChip were regressed out using
ComBat [40] as previously described [19]. The multivariate logistic
regression model was adjusted for covariates age, gender, smoking
status and HPV status. The ability of mdSI indices to classify HNSCC
cancer cases and cancer free controls was assessed using receiver op-
erating characteristic (ROC) curves and corresponding Area Under the
ROC Curve (AUC) values using the R package pROC [41].
For the HNSCC survival dataset, we performed univariate and
multivariate Cox proportional hazard analyses using the R package
survival (https://cran.r-project.org/web/packages/survival/index.
html). For each model, the proportional hazards assumption for a Cox
regression was tested to check for any violation using function cox.zph
implemented in the R package.
The multivariate Cox proportional hazards regression model was
adjusted for age, gender, smoking status (ever/never), tumour stage
(stage I&II (low)/ III&IV (high)), HPV16 E6 serology (positive/nega-
tive), alcohol consumption (ever/never) and ACE27 categorisation.
Furthermore, to address potential sources of unwanted technical var-
iation, we performed Surrogate Variable Analysis (SVA) [42–44]. We
created a full model matrix (a model matrix containing mdNLR (above/
below median value), mdLMR (above/below median value), OS status,
survival time, HPV16 E6 seropositivity status, smoking status, age,
gender, alcohol consumption, ACE27 categorisation and low/high stage
of tumour) and a null model matrix (a model matrix containing mdNLR
(above/below median value), mdLMR (above/below median value),
HPV16 E6 seropositivity status, smoking status, age, gender, alcohol
consumption, ACE27 categorisation and low/high stage of tumour)
from our phenotype data. Ten surrogate variables were derived as the
most variable technical artefacts in our data. The multivariate Cox
proportional hazards regression model was further adjusted for these
ten surrogate variables along with the covariates mentioned above.
Kaplan-Meier survival curves were plotted using the R package surv-
miner (https://github.com/kassambara/survminer).
Finally, a Wilcoxon rank sum test was performed to compare the
mean values of myeloid diﬀerentiation associated 5 CpG sites [24] in
HNSCC cases who died during the follow-up period and those who re-
mained alive.
Results
Sample characteristics
HNSCC case-control dataset
The sample characteristics including demographic and clinical data
for the HNSCC case-control dataset have been previously described [19]
and are shown in Supplementary Table 1. The mean age of the parti-
cipants was 60 years, with 69% men. The mean mdNLR and mdLMR
were 2.35 (SD=1.36) and 6.25 (SD=5.37) respectively.
HNSCC survival dataset
The sample characteristics including demographic and clinical data
for HN5000 are shown in Table 1. Four hundred and seven people with
HNSCC were included in this study. The mean age of the participants
was 59 years, with 77% men. For lifestyle associated risk factors, 97%
were ever alcohol consumers, 69% had a smoking history (ever smo-
kers). The majority of the tumours (85%) were of high stage (stage III or
IV) vs low stage (stage I and II). Of all the HNSCC samples analysed for
HPV16 E6 protein seropositivity, 67% of the samples were positive
while 33% were negative. The mean mdNLR and mdLMR were 2.4
(SD=2.51) and 3.5 (SD=1.42), respectively.
Table 1
Sample characteristics of HNSCC survival dataset at baseline.
Characteristics N (%)
Mean age (range) 59.24 (30–94) 407 (100%)
Mean mdNLR (SD) 2.43 (2.51)
Mean mdLMR (SD) 3.45 (1.42)
Gender Male 319 (78%)
Female 88 (22%)
Drinking status Never-drinker 14 (3%)
Ever-drinker 393 (97%)
Smoking status Never-smoker 111 (27%)
Ever-smoker 296 (73%)
Clinical stage Low (TNM Stage 1 or 2) 55 (14%)
High (TNM Stage 3 or 4) 352 (86%)
HPV16 E6 seropositivity Absent 133 (33%)
Present 274 (67%)
Tumour site Oral cavity 18 (4%)
Oropharynx 389 (96%)
Adult Comorbidity Evaluation 27 (ACE
27) categorisation
No comorbidity 212 (52%)
Mild comorbidity 120 (30%)
Moderate
decompensation
65 (16%)
Severe decompensation 6 (1%)
Unknown 4 (1%)
mdNLR=Methylation derived Neutrophil-to-Lymphocyte Ratio.
mdLMR=Methylation derived Lymphocyte-to-Monocyte Ratio.
SD= Standard Deviation.
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Methylation-derived systemic inﬂammation indices are associated with the
risk of HNSCC
We observed elevated estimated neutrophil (P= 1.57× 10−8) and
monocyte (P= 0.0770) counts and lower lymphocyte count
(P= 6.49×10−10) in HNSCC cases compared to controls
(Supplementary Fig. 2A). A higher mdNLR was seen in HNSCC cases
compared to controls (P=1.53× 10−9, Fig. 1A), while elevated
mdLMR was observed in controls compared to cases (P=2.55×10−7,
Fig. 1B). Using a multivariate logistic regression model including age,
gender, smoking status and HPV16-E6 serology status as covariates,
elevated mdNLR (OR=3.25, 95% CI=2.14–5.34, P=4×10−7) and
a lower mdLMR (OR=0.88, 95% CI= 0.81–0.90, P= 2.0× 10−3)
Survival status 
m
dN
LR
 
C D 
Survival status 
m
dL
M
R
 
m
dN
LR
 
m
dL
M
R
 
A B 
Case-control status Case-control status 
Fig. 1. Methylation derived systemic inﬂammation indices in the HNSCC case-control and survival datasets. A. mdNLR in pre-treatment HNSCC cases and controls. B.
mdLMR in pre-treatment HNSCC cases and controls. C. mdNLR in HNSCC cases who died during follow-up and those who were alive. D. mdLMR in HNSCC cases who
died during follow-up and those who were alive.
Table 2
Association between methylation-derived systemic inﬂammation indices (mdNLR, mdLMR) and case-control status in HNSCC dataset (n=183).
Study variables Univariate model OR (95% CI) (n=183) P-value Multivariate model OR (95% CI) (n= 183) P-value
mdNLR (continuous) 2.82 (1.96–4.33) 2.22× 10−7 3.25 (2.14–5.34) 4.03× 10−7
Age – – 0.98 (0.95–1.01) 0.12
Gender
Female – – Ref. NA
Male – – 0.81 (0.37–1.77) 0.59
Smoking status – –
Current – – Ref. NA
Former – – 1.04 (0.39–2.78) 0.94
Never – – 0.28 (0.08–0.88) 0.03
HPV status – –
HPV16 E6 negative – – Ref. NA
HPV16 E6 positive – – 3.44 (1.41–8.92) 0.01
mdLMR (continuous) 0.91 (0.84–0.97) 0.014 0.88 (0.81–0.9) 1.92× 10−3
Age – – 0.99 (0.96–1.0) 0.50
Gender
Female – – Ref. NA
Male – – 0.52 (0.24–1.1) 0.09
Smoking status – –
Current – – Ref. NA
Former – – 0.76 (0.30–1.9) 0.56
Never – – 0.23 (0.07–0.7) 0.01
HPV status – –
HPV16 E6 negative – – Ref. NA
HPV16 E6 positive – – 4.80 (2.09–12.0) 3.99× 10−4
mdNLR=Methylation derived Neutrophil-to-Lymphocyte Ratio.
mdLMR=Methylation derived Lymphocyte-to-Monocyte Ratio.
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were associated with increased odds of being a HNSCC case (Table 2).
The methylation-derived systemic inﬂammation indices alone were
able to distinguish HNSCC cases and controls compared to covariates:
age, gender, smoking status and HPV status (Supplementary Fig. 3).
Interestingly, mdNLR (AUC=0.76 (95% CI= 0.69–0.83) and mdLMR
(AUC=0.72 (95% CI=0.65–0.80) alone had similar AUC for distin-
guishing HNSCC cases from controls (P= 0.35 for diﬀerence). Adding
covariates to the systemic inﬂammation indices improved the mdNLR
AUC in distinguishing HNSCC cases from controls compared to mdLMR
(AUCmdNLR+cov= 0.82 (95% CI=0.76–0.88), AUCmdLMR+cov= 0.75
(95% CI=0.68–0.82), P=0.05 for diﬀerence) (Supplementary Fig. 3).
mdLMR is associated with overall survival in HNSCC
In the HNSCC survival dataset, 109 (27%) participants died during
the median follow-up period of 4.54 years (range 0.18–6.41 years).
Leukocyte cell counts indicated that neutrophil (P=0.02) and
monocyte (P=9.9× 10−5) counts were elevated while lymphocyte
count (P=0.004) was lower in HNSCC cases with poor survival
(Supplementary Fig. 2B).
Elevated mdNLR was observed in HNSCC patients who died during
the follow-up period (P=0.004, Fig. 1C) while mdLMR was elevated in
HNSCC patients who remained alive compared to those who died
during follow-up (P=1.1× 10−5, Fig. 1D).
There were no serious violations of the proportionality assumption
across the predictors used in the univariate and multivariate analysis.
Univariate Cox proportional hazards regression analysis (Fig. 2 and
Table 3) showed that lower mdNLR was associated with a reduced risk
of death (HR=0.55, 95% CI=0.38–0.81, P=0.00253), while lower
mdLMR was associated increased risk of death (HR=2.38, 95%
CI=1.66–3.55, P=0.00002).
The results from our multivariate Cox proportional hazards regres-
sion analysis including age, gender, tumour stage, smoking status,
HPV16 E6 serology status, alcohol consumption and ACE 27 categor-
isation as covariates, showed that lower mdNLR was not signiﬁcantly
associated with decreased risk of death (HR=0.68, 95%
CI=0.46–1.00, P=0.0501) while the converse was observed for
mdLMR (HR=1.96, 95% CI=1.30–2.95, P=0.0013), as shown in
Table 3. Further adjustment for HNSCC tumour site (oral and OPC) did
not attenuate our ﬁndings (Supplementary Table 2) for both mdNLR
(HR=0.69, 95% CI=0.46–1.02, P=0.0597) and mdLMR
(HR=1.97, 95% CI= 1.31–2.97, P=0.0012). Importantly, adjusting
for technical artefacts by surrogate variable analysis did not attenuate
our ﬁndings for mdLMR (HR=2.31, 95% CI= 1.41–3.77,
P=0.0009), or mdNLR (HR=0.65, 95% CI= 0.38–1.09,
P=0.1042).
Chronological age, advanced stage (stage III/IV) and ever smoking
(current/former) were associated with poorer OS in HNSCC. In
contrast, HPV16 E6 seropositivity (Table 3) and OPC (Supplementary
Table 2) were associated with better OS. Elevated mdNLR and lower
mdLMR were observed in HPV negative and ever smoker HNSCC cases
(Supplementary Fig. 4).
We found that all ﬁve CpGs associated with myeloid cell diﬀer-
entiation (suggested to be a surrogate for mdNLR) were hypermethy-
lated in HNSCC patients who remained alive during the follow-up
period (Table 4, Supplementary Fig. 5).
Discussion
In the present study, we have identiﬁed that methylation-derived
systemic inﬂammation indices may be used to distinguish HNSCC cases
and controls. The mdSI indices provide a slight improvement over
covariates (age, gender, smoking and HPV status) in distinguishing
HNSCC cases from controls. Intriguingly, lower mdLMR was associated
with poorer OS.
We observed an elevated methylation-derived circulating neutrophil
and monocyte count and a decreased lymphocyte count in HNSCC cases
compared to controls. Similarly, HNSCC cases with poor OS showed
elevated neutrophil and monocyte cell counts and a lower lymphocyte
count. Our ﬁndings concur with previous reports on cell count-based
leukocyte measurements in HNSCC development and progression
[45–47].
We utilised mdNLR and mdLMR to understand the contribution of
systemic inﬂammation in HNSCC development and survival. Findings
from the present study suggests an association of mdSI indices with the
presence of HNSCC and OS similar to previous cell count based reports
[16,18]. Interestingly, our DNA methylation-derived estimates of NLR
and LMR were similar to the cell count based measure of SI [18,48].
The similarities between DNA methylation and cell count based in-
ﬂammation indices strengthens the utility of mdSI indices as a valuable
research tool to estimate SI in the absence of cell count based mea-
surement, especially in prospective studies.
Although the mdSI indices are associated with the presence of
HNSCC and with OS, these associations may also be driven by exposure
to inﬂammation-associated risk factors of HNSCC such as smoking and
HPV status that are also associated with poor prognosis in HNSCC [6].
Our ﬁndings of an elevated mdNLR and lower mdLMR in HPV negative
and ever smoking HNSCCs are in agreement with the previous ob-
servations [14]. These observations may be indicative of the potential
biological diﬀerences between HPV positive and negative tumours.
HPV eﬀectively evades the innate immune system by conﬁning gene
and protein synthesis to the epithelial cells hence, only nominal
amounts of replicating virus are exposed to the immune system [49,50].
Our ﬁndings of elevated mdLMR and lower mdNLR in HPV-positive
HNSCC may therefore be reﬂective of an innate immune response.
Fig. 2. Overall survival curve for methylation derived systemic inﬂammation indices A. mdNLR (above and below median) and B. mdLMR (above and below
median).
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Smoking is associated with increased systemic inﬂammation [51].
Lifetime smoking related tobacco exposure measured by pack years was
recently shown to be associated with elevated NLR [52]. Indeed, our
recent DNA methylation study identiﬁed an altered number of immune
cells in response to smoking [53].
We observed an association between mdSI indices (elevated mdNLR
and lower mdLMR) and increased odds of being an HNSCC case. Our
results concur with the previously published work validating the SI
indices derived using DNA methylation data [14–16,18]. Importantly,
the level of mdNLR derived inﬂammation index were similar to the NLR
derived using cell counts in HNSCC [16,48]. Previous studies have re-
ported a higher monocyte count and a lower lymphocyte count asso-
ciated with poor clinical outcome in HNSCC [54–56]. Our ﬁnding of
lower LMR associated with reduced OS validates previous reports that
cell count based pre-treatment LMR may be an independent prognostic
marker in cancers, including HNSCC [18,57].
Altered SI (NLR, LMR) derived from either DNA methylation-based
data or based on cell counts are reﬂective of systemic inﬂammation
[13]. Previous studies have suggested a vicious cycle of interaction
between tumour cells and cells of myeloid origin such as neutrophils
and monocytes through cytokines which leads to neo-angiogenesis and
poor treatment response [46,47,58,59]. On the other hand, lympho-
cytes play a critical role in strengthening the host immune response
against cancer [55]. In fact, the levels of tumour inﬁltrating
Table 3
Association between methylation-derived systemic inﬂammation indices (mdNLR, mdLMR) and overall survival in HNSCC cases.
Study variables Overall survival (n= 407)
Univariate model HR (95% CI) P-value Multivariate model HR (95% CI) P-value
mdNLR (below median vs. above median) 0.55 (0.38–0.81) 0.0025 0.68 (0.46–1.00) 0.0501
Age – – 1.03 (1.01–1.05) 0.0009
Gender
Female – – Ref. NA
Male – – 1.07 (0.66–1.73) 0.7986
Stage
Low (T1&T2) – – Ref. NA
High (T3&T4) – – 2.62 (1.34–5.12) 0.0050
Smoking status
Never – – Ref. NA
Ever – – 2.21 (1.20–4.09) 0.0110
HPV status
HPV16 E6 negative – – Ref. NA
HPV16 E6 positive – – 0.32 (0.22–0.49) 4.9× 10−8
Drinking
Never – – Ref. NA
Ever – – 1.03 (0.67–1.58) 0.9024
Adult Comorbidity Evaluation 27 (ACE 27) categorisation
No co-morbidity – – Ref. NA
Mild comorbidity – – 1.49 (0.92–2.41) 0.1014
Moderate decompensation – – 1.50 (0.88–2.55) 0.1323
Severe decompensation – – 4.66 (1.75–12.43) 0.0021
Unknown – – 5.23 (1.21–22.63) 0.0270
mdLMR (below median vs. above median) 2.38 (1.59–3.55) 2.1× 10−5 1.96 (1.30–2.95) 0.0013
Age – – 1.03 (1.01–1.05) 0.0141
Gender
Female – – Ref. NA
Male – – 1.16 (0.71–1.89) 0.5610
Stage
Low (T1&T2) – – Ref. NA
High (T3&T4) – – 2.56 (1.30–5.02) 0.0063
Smoking status
Never – – Ref. NA
Ever – – 2.34 (1.26–4.34) 0.0069
HPV status
HPV16 E6 negative – – Ref. NA
HPV16 E6 positive – – 0.33 (0.22–0.49) 5.5× 10−8
Drinking
Never – – Ref. NA
Ever – – 1.11 (0.72–1.73) 0.6343
Adult Comorbidity Evaluation 27 (ACE 27) categorisation
No co-morbidity – – Ref. NA
Mild comorbidity – – 1.44 (0.89–2.32) 0.1365
Moderate decompensation – – 1.44 (0.84–2.45) 0.1854
Severe decompensation – – 4.53 (1.71–12.05) 0.0024
Unknown – – 5.00 (1.14–21.94) 0.0327
mdNLR=Methylation derived Neutrophil-to-Lymphocyte Ratio.
mdLMR=Methylation derived Lymphocyte-to-Monocyte Ratio.
Table 4
DNA methylation (beta values) of myeloid cell diﬀerentiation associated CpGs
in HNSCC survival dataset.
Myeloid diﬀerentiation CpGs Mean Alive (SD) Mean Dead (SD) P-valuea
cg00901982 0.23 (0.09) 0.20 (0.09) 0.0007
cg25938803 0.28 (0.08) 0.26 (0.08) 0.0012
cg01591037 0.31 (0.10) 0.29 (0.10) 0.0249
cg03621504 0.20 (0.08) 0.18 (0.08) 0.0313
cg10456459 0.33 (0.11) 0.28 (0.10) 0.0003
a Wilcoxon rank sum test.
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lymphocytes (TILs) are known to predict survival in OPC patients [60].
We observed an increase in baseline methylation-derived myeloid cell
counts (neutrophils and monocytes) and a decrease in baseline lym-
phocytes in incident HNSCC cases and cases with poor survival. Thus,
our ﬁndings underline the signiﬁcance of immune homeostasis in
HNSCC development and progression.
Strengths of our study include the use of two datasets, giving us the
ability to explore varied roles for mdSI indices in distinguishing pre-
treatment HNSCC cases and controls, as well as in relation to survival.
We performed multivariate analyses adjusting for appropriate potential
confounders and possible sources of technical variation.
Our study is not without limitations. Firstly, the sample size for both
the case-control and OS studies was small, moreover, we were unable to
identify independent prospective datasets to validate our ﬁndings. This
is attributed to limited published and publicly-available HNSCC data-
sets with genome-wide DNA methylation information on whole blood.
Secondly, in the absence of genetic instruments for the cell count based
systemic inﬂammation index, we are unable to evaluate causality of the
observed association using Mendelian randomization [61] nor can we
rule out reverse causation in the HNSCC case-control study. Thirdly, we
were unable to compare mdSI indices to cell count based SI indices due
to the lack of availability of directly measured blood cell type propor-
tions for the studied datasets. In spite of these limitations, the con-
ﬁdence in our measured methylation-derived SI is strengthened by (i)
previous studies that have validated the use methylation-derived cell
counts in estimating SI [19,24] and (ii) similarities between our mdSI
indices and previously published cell count based SI. Finally, we had
limited information on the presence of oral inﬂammatory conditions
such as oral lichen planus, Behcet's disease, and recurrent aphthous
stomatitis in our datasets, so we were unable to adjust for these factors
in the statistical models. However, we did account for the presence of
chronic diseases associated with inﬂammatory conditions by adjusting
for the ACE-27 score in our statistical models.
In conclusion, we have demonstrated that systemic inﬂammation
indices are associated with the presence of HNSCC. Further, the mdSI
indices are suﬃcient to distinguish HNSCC case and controls. In the
HNSCC survival dataset, lower mdLMR was associated with poorer OS.
The mdSI indices may be useful as a research tool for predicting high-
risk HNSCC, especially HPV-negative HNSCC where there is a lack of
reliable biomarkers of detection, although this would require rigorous
validation in large prospective studies. The mdSI indices will be parti-
cularly helpful in prospective studies where the estimates of leukocyte
subtypes were not recorded at recruitment. It remains to be tested
whether mdSI measures SI independent of acute phase proteins such as
CRP. Finally, we would be interested in testing whether mdSI in cir-
culation is reﬂective of inﬂammation status in tumours.
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